The findings will be presented by health system researchers Nov. 6-10 at the Society for Immunotherapy of Cancer Annual Meeting, according to a Nov. 8 news release from Cleveland Clinic.
The first phase of the vaccine trial was launched in 2021 by the Defense Department and conducted at Cleveland Clinic in partnership with Anixa Biosciences. The second phase will launch in 2025 to determine the vaccine’s efficacy over two to three years.
The vaccine targets a protein present in most triple-negative breast cancers. The vaccine is designed to prompt the immune system if cancer develops, attack the tumor and keep it from growing, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
